Knowledge Library
WuXi Discovery Services Newsletter: March 2021
Immuno-Oncology Platform to Enable Discovery from Target to Drug
Aug 2021: Wuxi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models.
Validation of GVHD in mouse model for preclinical efficacy screen
AACR Annual meeting 2021 Na Xu, Ya Zhang, Rou Xie, Lijun Jia, Yingying Cai, Qing Lin Oncology and Immunology Unit, WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China Background Bone marrow transplantation has been successfully and widely used to treat diseases such as leukemia and lymphomas. However, the complication Graft …Read More >
Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer
AACR Annual meeting 2021 Authors: Zhixiang Zhang1, Feifei Fan2, Xiaohe Shi2, Xiangyang Zuo2, Qingyang Gu2, Qunsheng Ji1. 1 WuXi AppTec, Shanghai, China; 2 WuXi AppTec, Jiangsu, China Corresponding Author: Qunsheng Ji. Email: ji_qunsheng@wuxiapptec.com Background Many cancer types are driven by specific gene aberrances, like gene fusions, mutations and copy number changes. It has led to …Read More >
Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics
AACR Annual meeting 2021 Ting Ni, Zhixiang Zhang, Xuzhen Tang, Hui Qi, Jingying Zhang, Ke Mao, Wenting Shi, Qingyang Gu, Qunsheng Ji WuXi AppTec, Suzhou, China Abstract Recent advances in cancer biology and diagnosis are providing more targeted approaches to treat cancers. Therapy targeting the specific oncogenic driver could inhibit tumor progression and helps to …Read More >
Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies
Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation is G12C, which comprises nearly 15% of lung adenocarcinomas, 8% of colorectal carcinomas and 4% of pancreatic adenocarcinomas. AMG-510 from Amgen and MRTX849 from Mirati Therapeutics, both targeting the KRASG12C mutant, have shown encouraging results …Read More >
Translational Oncology
Biomarker discovery Mouse clinical trial 61 PDX-derived primary cancer cell lines Drug-resistant xenograft models Combination therapy platform including radiation World leading genome sequencing and bioinformatics capability
Patient-Derived Xenograft (PDX) Tumor Models
One of the largest collection of Patient-Derived Xenograft (PDX) Tumor Models in Asia with gene expression/mutation profiling 1200 PDX models Collection of PDX models prevalent in Asia 800+ PDX models with genetic profiling Searchable online database with mobile APP Integrated online database for PDX, CDX & Syngeneic tumor models with mobile App PDX with oncogene …Read More >
